Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures.

Autor: Alcaniz J; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Winkler L; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Dahlmann M; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Becker M; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Orthmann A; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Haybaeck J; Department of Neuropathology, Diagnostic & Research Center for Molecular BioMedicine, Institute of Pathology, Medical University of Graz, Graz, Austria.; Center for Biomarker Research in Medicine, Graz, Austria.; Institute of Pathology, Neuropathology, and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria., Krassnig S; Department of Neuropathology, Diagnostic & Research Center for Molecular BioMedicine, Institute of Pathology, Medical University of Graz, Graz, Austria., Skofler C; Center for Biomarker Research in Medicine, Graz, Austria., Kratzsch T; Department of Neurosurgery, Charité Universitätsmedizin, Berlin, Germany., Kuhn SA; Department of Neurosurgery, Ernst von Bergmann Hospital, Potsdam, Germany., Jödicke A; Department of Neurosurgery, Vivantes Hospital Berlin Neukölln, Berlin, Germany., Linnebacher M; Department of Surgery, Molecular Oncology and Immunotherapy, University Medical Center Rostock, Rostock, Germany., Fichtner I; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Walther W; Experimental Pharmacology and Oncology GmbH, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Berlin, Germany.; Experimental and Clinical Research Center, Charité Universitätsmedizin, Berlin, Germany., Hoffmann J; Experimental Pharmacology and Oncology GmbH, Berlin, Germany.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Apr 11; Vol. 13, pp. 1129627. Date of Electronic Publication: 2023 Apr 11 (Print Publication: 2023).

Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine.

Autor: Kratzsch T; Department of Neurosurgery, Charité University Hospital, Berlin, Germany., Piffko A; Department of Neurosurgery, Charité University Hospital, Berlin, Germany., Broggini T; Department of Physics, University of California, San Diego, La Jolla, CA, United States., Czabanka M; Department of Neurosurgery, Charité University Hospital, Berlin, Germany., Vajkoczy P; Department of Neurosurgery, Charité University Hospital, Berlin, Germany.

Publikováno v: Frontiers in oncology [Front Oncol] 2020 Feb 19; Vol. 10, pp. 174. Date of Electronic Publication: 2020 Feb 19 (Print Publication: 2020).

Everolimus delays growth of patient-derived glioblastoma xenografts by inhibition of the mTor downstream pathway

Autor: Kratzsch, T, Vajkoczy, P, Kuhn, SA

Publikováno v: 64. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC); 20130526-20130529; Düsseldorf; DOCMI.13.09 /20130521/

Objective: Targeted therapies against activated signaling pathways are important in the treatment of human malignancies. In glioblastomas, the inactivated tumor suppressor PTEN causes activation of mTOR, explaining the rationale of mTOR inhibitors to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a94f442225d2d5e92451bc5b44841c4

Designing an mHealth application for informal carers concerning the management of behavioural and psychological symptoms of dementia: a need analysis survey.

Autor: Jagoda, Thilanka^1,2 (AUTHOR) thilanka@sjp.ac.lk, Dharmaratne, Samath D.^1,3 (AUTHOR), Rathnayake, Sarath⁴ (AUTHOR)

Publikováno v: BMC Health Services Research. 8/14/2024, Vol. 24 Issue 1, p1-14. 14p.

Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.

Autor: Kratzsch T; Department of Neurosurgery, Charité University Hospital, Chariteplatz 1, 10117, Berlin, Germany. tobias.kratzsch@charite.de., Kuhn SA; Department of Neurosurgery, Ernst von Bergmann Hospital, Potsdam, Germany., Joedicke A; Department of Neurosurgery, Vivantes Hospital Berlin Neukölln, Berlin, Germany., Hanisch UK; Institute of Neuropathology, University Hospital, Göttingen, Germany.; Paul Flechsig Institute for Brain Research, University of Leipzig, Leipzig, Germany., Vajkoczy P; Department of Neurosurgery, Charité University Hospital, Chariteplatz 1, 10117, Berlin, Germany., Hoffmann J; Experimental Pharmacology and Oncology GmbH, Berlin, Germany., Fichtner I; Max Delbrueck Center for Molecular Medicine, Berlin, Germany.

Publikováno v: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2018 May; Vol. 144 (5), pp. 809-819. Date of Electronic Publication: 2018 Feb 09.